New drug combo aims to wipe out hidden myeloma cells after transplant

NCT ID NCT05344833

Recruiting now Disease control Sponsor: University of Illinois at Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of two drugs, isatuximab and lenalidomide, can clear remaining cancer cells in multiple myeloma patients who still have minimal residual disease (MRD) after an autologous stem cell transplant. About 50 adults will receive the drugs as maintenance therapy for up to 39 cycles. The main goal is to see how many patients become MRD-negative at one year, which could mean a lower chance of relapse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab and lenalidomide
What this could lead to: If successful, this could lead to a maintenance therapy that helps eliminate remaining cancer cells after transplant, potentially delaying relapse in multiple myeloma.
What could go wrong: This is a small, early-phase (phase 2) trial with only 50 participants. The combination may cause side effects like blood clots or infections, and it's not yet known if it will improve survival or lead to long-term disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
University of Illinois at Chicago
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.